trending Market Intelligence /marketintelligence/en/news-insights/trending/ZiX4NVSuOKr7vw9nmbKdVQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Mérieux Equity invests in French pharmaceutical laboratory Addmedica

Banking Essentials Newsletter December Edition Part 2

Banking Essentials Newsletter - November Edition

University Essentials | COVID-19 Economic Outlook in Banking: Rates and Long-Term Expectations: Q&A with the Experts

Estimating Credit Losses Under COVID-19 and the Post-Crisis Recovery


Mérieux Equity invests in French pharmaceutical laboratory Addmedica

Mérieux Equity Partners SAS made an investment in French pharmaceutical laboratory Addmedica SAS through its Mérieux Participations 3 SLP fund.

The private equity firm became the reference shareholder of the company in partnership with founders François Anger and Bernard Dauvergne.

Addmedica develops and markets medicinal products and medical devices for rare diseases, including a benchmark treatment for inherited blood disorder sickle cell disease. The company will use the capital to expand its global footprint and product portfolio.

Duteil et Associés Law Firm and Advance Capital provided support to Mérieux Equity.